ClinicalTrials.Veeva

Menu

Study to Determine the Pharmacokinetics and Pharmacodynamic Effects of Phenylephrine on BP Via IV

W

West-Ward Pharmaceutical

Status and phase

Enrolling
Phase 4

Conditions

Hypotension

Treatments

Drug: Phenylephrine

Study type

Interventional

Funder types

Industry

Identifiers

NCT02323399
1420RDP009

Details and patient eligibility

About

The primary objective of this study is to evaluate the dose effect of Phenylephrine Hydrochloride Injection on the treatment of clinically relevant decreased blood pressure in the pediatric population, ≥12 to 16 year old patients undergoing general and neuraxial anesthesia.

The secondary objectives are to describe changes in blood pressure and heart rate, time to onset and to maximal response, and the duration of response; to assess the safety of the product in this population; and to characterize the pharmacokinetics of phenylephrine hydrochloride.

Full description

This is a Phase 4 multi-center, randomized open-label study in 100 subjects aged ≥12 to 16 years who experience a decrease in blood pressure during a procedure requiring general or neuraxial anesthesia. At least 300 subjects will be enrolled in this study. It is anticipated that up to 33% of enrolled subjects will actually experience a decrease in blood pressure that requires treatment and so will receive Phenylephrine Hydrochloride Injection (PHI). There are 12 possible randomization assignments: one of six initial treatments PHI will be initially administered to approximately 50 subjects as an intravenous bolus (IV-B) at Low (1 μg/kg), Med (3 μg/kg), or High (5 μg/kg) level; PHI will be initially administered to approximately 50 subjects as a continuous intravenous infusion (IV-I) at Low (0.25 μg/kg/min), Med (0.75 μg/kg/min), or High (1.25 μg/kg/min) level]; each initial treatment group will have two pharmacokinetics (PK) sampling schedules.

Enrollment

100 estimated patients

Sex

All

Ages

12 to 16 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Subject's age is between ≥12 and 16 years, inclusive
  2. Subject is scheduled for a procedure that requires general or neuraxial anesthesia
  3. Subjects must have normal or clinically acceptable physical exam
  4. Subjects with controlled diabetes prior to entry must have a mean systolic/diastolic office blood pressure ≤128/78 mmHg (sitting, after 5 minutes of rest)
  5. Females must have a urine or serum pregnancy test (Human Chorionic Gonadotropin) that is negative at Screening and Day 1
  6. Subject's parent or legal guardian gives informed consent and subject gives assent.

Exclusion criteria

  1. Subject has a contraindication to vasoconstrictor therapy for control of blood pressure
  2. Subject has participated in other clinical trials for investigational drugs and/or devices within 30 days prior to enrollment
  3. Subject has any serious medical condition which, in the opinion of the investigator, is likely to interfere with study procedures
  4. Subjects who have a history of any clinically significant local or systemic infectious disease within four weeks prior to initial treatment administration
  5. Subjects who are positive for hepatitis B surface antigen or hepatitis C antibody
  6. Subjects taking antihypertensive medication
  7. Subject is moribund (death is likely to occur in less than 48 hours)
  8. Females who are pregnant, nursing or unwilling to use/practice adequate contraception.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

100 participants in 1 patient group

Phenylephrine
Experimental group
Description:
Phenylephrine Hydrochloride Injection, USP (United States Pharmacopeia) 10 mg/mL label claim
Treatment:
Drug: Phenylephrine

Trial contacts and locations

10

Loading...

Central trial contact

J. Barton Kalis

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems